È­¼øÀü³²´ëº´¿ø ³²Åñ١¤Á¤Àç¿í¡¤Á¶ÀÍÁØ ±³¼öÆÀ, ROJ³í¹®»ó ¼ö»ó

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö °ÔÀ硦¿ì¼ö¼º¡¤¿¬±¸¼º°ú ÀÎÁ¤
2023. 06.05(¿ù) 17:42È®´ëÃà¼Ò
(¿ÞÂʺÎÅÍ)È­¼øÀü³²´ëº´¿ø ¹æ»ç¼±Á¾¾çÇаú ³²Åñ١¤Á¤Àç¿í¡¤Á¶ÀÍÁØ ±³¼ö


È­¼øÀü³²´ëÇб³º´¿øÀº ¹æ»ç¼±Á¾¾çÇаú ³²Åñ١¤Á¤Àç¿í¡¤Á¶ÀÍÁØ ±³¼öÆÀÀÌ ÃÖ±Ù ºÎ»ê ÆĶó´ÙÀ̽ºÈ£ÅÚ¿¡¼­ ¿­¸° ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ¿¡¼­ ¡®ROJ(Radiation Oncology Journal)¡¯ ³í¹®»óÀ» ¼ö»óÇß´Ù°íÀÏ ¹àÇû´Ù.

¡®ROJ ³í¹®»ó¡¯Àº Àü³âµµ ´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö¿¡ °ÔÀçµÈ ³í¹® Áß¿¡ °¡Àå ¿ì¼öÇÑ ³í¹®À» ¼±Á¤ÇØ ¼ö¿©ÇÏ´Â »óÀÌ´Ù.

³²Åñ١¤Á¤Àç¿í¡¤Á¶ÀÍÁØ ±³¼öÆÀÀº ¡®Á¤À§ üºÎ ¹æ»ç¼± Ä¡·á¸¦ ¹Þ´Â ±¹¼Ò °£¼¼Æ÷¾ÏÁ¾ ȯÀÚÀÇ ¿¹ÈÄ ÀÎÀڷμ­ÀÇ PIVKA-II(PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy)¡¯¶ó´Â ³í¹®À¸·Î ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È¾Ò´Ù.

ÀÌ ³í¹®Àº Á¤À§Ã¼ºÎ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº °£¾Ï ȯÀڵ鿡°Ô¼­ °£¾ÏÇ¥ÁöÀÚÀÇ ÇϳªÀÎ PIVKA-II ¼öÄ¡°¡ Ä¡·á ÈÄ °¨¼ÒÇ߰ųª, ÀÏÁ¤ ¼öÄ¡ ÀÌÇÏ·Î ³·¾ÆÁø ȯÀÚ±ºÀÇ ±¹¼ÒÁ¾¾çÁ¦¾îÀ²°ú ¹«ÁøÇà»ýÁ¸À²ÀÌ À¯ÀÇÇÏ°Ô ¾çÈ£ÇßÀ½À» ±Ô¸íÇß´Ù.

È­¼øÀϺ¸ mire5375@hanmail.net
ÀÌ ±â»ç´Â È­¼øÀϺ¸ ȨÆäÀÌÁö(http://www.hwasun1.com)¿¡¼­ ÇÁ¸°Æ® µÇ¾ú½À´Ï´Ù.

¹®ÀÇ ¸ÞÀÏ : mire5375@hanmail.net